Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on January 23, 2008, to report its financial results for the fourth quarter and full year ended December 31, 2007. The filing itself is a notification that a press release containing these results has been issued. Investors should refer to the press release (Exhibit 99.1) for detailed financial performance information. The company provided both GAAP and non-GAAP financial metrics. Notably, Gilead provided explanations for its non-GAAP reporting, which excludes certain items such as after-tax stock-based compensation expense and, for 2006, purchased in-process R&D expenses from acquisitions. Management believes these non-GAAP measures offer valuable insights for investors by focusing on core operational performance, complementing the standard GAAP reporting.
Key Highlights
- 1Gilead Sciences announced its financial results for the fourth quarter and full year ended December 31, 2007, via press release on January 23, 2008.
- 2The 8-K filing serves as notification and incorporates the press release as Exhibit 99.1.
- 3The company reported both GAAP and non-GAAP financial results.
- 4Non-GAAP financial measures exclude after-tax stock-based compensation expense for both 2007 and 2006 periods.
- 5For 2006, non-GAAP results also excluded purchased in-process R&D expenses related to the Corus Pharma and Myogen acquisitions.
- 6Gilead management believes non-GAAP figures provide useful supplemental information for investors, aiding in the understanding of operational performance.
- 7The press release contains the substantive financial details of the reported periods.